Doctors call for balance between drug prices and profits

10/3/2013 | MedPage Today (free registration)

Cystic fibrosis treatment Kalydeco's price tag -- up to $373,000 per patient -- is unsustainable and violates drugmakers' responsibility to balance patient well-being with profit motives, three doctors write in the Journal of the American Medical Association. "The vast majority of patients cannot afford this financial burden and transferring the cost to private or federal insurers does not obviate the underlying problem -- an unsustainable pricing structure," the doctors write. Robert Beall, CEO of the Cystic Fibrosis Foundation, which invested in the drug's development, agrees that there is a need to strike a balance between patient needs and recovering the high costs of drug development.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY